Subscribe
genetic-dna
adike / shutterstock.com
1 December 2016Americas

Broad Institute and UCB to face off at CRISPR interference hearing

An interference proceeding on the patent rights to CRISPR/Cas9 will take place on December 6, with the judges setting the definition of the disputed invention as “the use of CRISPR in a method in a eukaryotic cell”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Broad Institute signs deals to boost medical research
12 October 2017   The Broad Institute of Harvard and MIT has committed itself to tackling complex therapeutic challenges concerning unmet medical needs, while also signing a deal on technology.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Americas
Broad Institute signs deals to boost medical research
12 October 2017   The Broad Institute of Harvard and MIT has committed itself to tackling complex therapeutic challenges concerning unmet medical needs, while also signing a deal on technology.

More on this story

Americas
Broad Institute signs deals to boost medical research
12 October 2017   The Broad Institute of Harvard and MIT has committed itself to tackling complex therapeutic challenges concerning unmet medical needs, while also signing a deal on technology.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?